India saw a raft of vaccine and drug approvals in 2021, backed by pandemic-related accelerated regulatory processes, and outlined its intent to step up biopharma innovation in the country.  Pharma wants some of the regulatory flexibility to stay, though experts are seeking increased transparency in the overall approach.

India has issued emergency approvals for a number of new vaccines and extended eligible age groups for others, while developers of potential drug therapies in China see both gains and setbacks. 

India has issued emergency approvals for a number of new COVID-19 vaccines and extended eligible age groups for others, while developers of potential drug therapies in China have seen both gains and setbacks. 

Clinical trial initiations in cell and gene therapies and immuno-oncology are seeing a spike as the COVID-19 experience has shown the benefits of beginning research early, Parexel’s executive vice president says. In an interview with Scrip, Sanjay Vyas discusses a range of topics from diversity to the advantages of block chain and growth in China